Morgan Stanley has hired senior dealmaker David Kostel as the vice chairman of its health-care investment banking group, ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Eli Lilly and Co. joined several other investors in a Series A round for a Boston biotech co-founded by the Longwood Fund that's developing a drug for a rare type of blood cancer.

Additionally, other companies like Scorpion Therapeutics are developing similar compounds, potentially narrowing Relay’s window of opportunity. Despite these challenges, analysts believe that Relay’s ...

Additionally, other companies like Scorpion Therapeutics are developing similar compounds, potentially narrowing Relay’s window of opportunity. Despite these challenges, analysts believe that ...

Data supplied by Morningstar and accurate on Sep 30, 2024. It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of ...

As of this writing, there are quite a few Quinques in this experience, and Scorpion is the most common one you can acquire. The Scorpion is basically a two-handed sword that can easily pierce ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. We appreciate the ...

RNA therapeutics have existed since the late 90s but have only come into focus in the last few years. This renewed interest has largely been attributed to the success of messenger RNA (mRNA) vaccines ...

March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the ...

The drug, a once-daily pill called Vykat XR, was developed by Soleno Therapeutics. “The approval of Vykat XR is a significant milestone for Soleno and, most importantly, for the PWS community ...